Bright Minds Biosciences Inc.
DRUG
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -265.86% | -15,429.38% | -423.06% | -2,355.60% | -382.70% |
| Total Depreciation and Amortization | -9.55% | -7.79% | -74.95% | 152.75% | 17.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -134.58% | 289.17% | 962.88% | 973.99% | 160.83% |
| Change in Net Operating Assets | 1,148.55% | -743.80% | 1,163.07% | -144.69% | 72.87% |
| Cash from Operations | -293.44% | -290.76% | -171.08% | -1,543.02% | -182.97% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.91% | -9.24% | -9.21% | -16.36% | -11.82% |
| Issuance of Common Stock | 97,216.84% | -71.85% | 12,069,900.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -121.40% | -- | -- | -- |
| Cash from Financing | 104,542.17% | -74.16% | 139,928.90% | 23.75% | 1,063.19% |
| Foreign Exchange rate Adjustments | 8,847.86% | -188.43% | -3,248.36% | -2,029.76% | -631.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10,372.11% | -88.19% | 6,739.28% | -1,746.71% | -151.15% |